Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic coverage: reducing the risks of partial compliance

P A Meredith1, H L Elliott

  • 1University of Glasgow, Western Infirmary, UK.

British Journal of Clinical Practice. Supplement
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The student clinicopathologic conference, a device for the teaching of advanced pathology.

Journal. Association of American Medical Colleges·2014
Same author

Comments on systematic review of clinical- and cost-effectiveness of candesartan and losartan in hypertension and heart failure.

International journal of clinical practice·2011
Same author

Preferential benefits of nifedipine GITS in systolic hypertension and in combination with RAS blockade: further analysis of the 'ACTION' database in patients with angina.

Journal of human hypertension·2010
Same author

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.

Journal of human hypertension·2009
Same author

Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity.

Expert opinion on investigational drugs·2005
Same author

Circulating endothelial cells in renal transplant recipients.

Transplantation proceedings·2005

Poor medication compliance, often due to underdosing, impacts blood pressure control. Amlodipine demonstrates superior efficacy in maintaining blood pressure, even with missed doses, due to its pharmacokinetic profile.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Cardiovascular Medicine

Background:

  • Inadequate patient compliance is a significant issue in antihypertensive therapy, often leading to underdosing and treatment interruptions.
  • The therapeutic consequences of poor compliance are substantial, particularly the periods of absent drug action.
  • Understanding the relationship between drug concentration, pharmacokinetics, and pharmacodynamics is crucial for effective blood pressure management.

Purpose of the Study:

  • To evaluate the impact of compliance on antihypertensive therapy effectiveness.
  • To compare the pharmacokinetic and pharmacodynamic profiles of various antihypertensive agents.
  • To determine the superiority of amlodipine in maintaining blood pressure control under varying compliance scenarios.

Main Methods:

Related Experiment Videos

  • Review of existing literature on antihypertensive drug compliance and therapeutic outcomes.
  • Analysis of pharmacokinetic and pharmacodynamic data for a range of antihypertensive agents.
  • Correlation of drug concentration-time profiles with blood pressure-lowering effects.

Main Results:

  • Poor compliance typically involves underdosing and therapy interruptions, leading to periods without drug effect.
  • A clear relationship exists between circulating drug concentration and blood pressure reduction for antihypertensives.
  • Amlodipine exhibits a favorable concentration-time profile and long elimination half-life compared to other agents.

Conclusions:

  • Amlodipine's pharmacokinetic properties make it superior for sustained blood pressure control.
  • The drug's profile ensures better therapeutic outcomes even with imperfect patient compliance or missed doses.
  • Optimizing antihypertensive therapy requires consideration of both drug characteristics and patient adherence.